Edited by
Dawn L. DeMeo, MD, MPH, Brigham and Women's Hospital/ Harvard Medical School, USA
James M Flanagan, PhD, Imperial College London, UK
Harold Snieder, PhD, University Medical Center Groningen, The Netherlands
Bea Wisman, PhD, University Medical Center Groningen, The Netherlands
Tomasz K Wojdacz, PhD, Pomeranian Medical University, Poland
Epigenetic biomarkers have significantly contributed to improved understanding of the origins and progression of disease. Moreover, increasing evidence shows that epigenetic biomarkers have potential for personalized medicine. However, routine use of epigenetic biomarkers in in-vitro diagnostics (IVD) is lagging behind the discoveries of new biomarkers. In this thematic series of Clinical Epigenetics, we discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of ageing and welcome both original research and reviews.
The sections of the collection include:
1. Types of epigenetic biomarkers and readiness for IVD use
- DNA methylation as biomarker
- Histone modification as biomarker
- Upcoming field of circulating free nucleosomes as biomarker
2. Progress towards clinical use of biomarker
- Biomarkers of environmental exposures and causality of the biomarker
- Disease predisposition biomarkers
- Biomarkers used for disease detection
- Clinical disease prevention and management: predictive and prognostic
- Monitoring of chronic disease
3. Single versus multiple biomarkers and risk scores
4. Major stages of clinical validation of the biomarker
5. Biomarker detection technologies suitable for IVD use and significance of bioinformatics
6. Ethics and regulatory aspects of IVD epigenetic biomarkers
This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. Please find out more about our journal and its policies, here. This collection is closed for submissions.